1) ASCO (6 weeks away): presenting data on IMGN853 plus the first clinical data for IMGN529 ... and data on two compounds developed for Sanofi, SAR3419 and SAR566658 ... data for Kadcyla
2) with Roche: reporting additional data on Kadcyla
The data will drive this stock; not the revenue numbers (in the short-term).
It is nice to see that amongst the phony messages pushing stock alert sites and the transparent 'thank yous' from those that allegedly benefited from them, that someone has added info that is really helpful.
Thanks for the update.
In a lot of ways it makes sense to farm information and place it here. We, as individual investors, can only help each other by doing that to make it more clear what is happening with Immunogen. I have been a part of the Tesla motors forum, and I truly believe that the free dissemination of information there allowed retail investors to have a leg up over both institutions and hedge funds.